UY33404A - Composiciones farmacéuticas topicas - Google Patents

Composiciones farmacéuticas topicas

Info

Publication number
UY33404A
UY33404A UY0001033404A UY33404A UY33404A UY 33404 A UY33404 A UY 33404A UY 0001033404 A UY0001033404 A UY 0001033404A UY 33404 A UY33404 A UY 33404A UY 33404 A UY33404 A UY 33404A
Authority
UY
Uruguay
Prior art keywords
weight
pharmaceutical compositions
skin
topic
compositions
Prior art date
Application number
UY0001033404A
Other languages
English (en)
Inventor
Willers Christoph
Mallwitz Henning
Evers Fritjof
Meyer Ricarda
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY33404A publication Critical patent/UY33404A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas tópicas que comprenden, en base al peso total de la compos ición : a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua, y d) 25 a 70% en peso d e una fase oleosa. Dichas composiciones son estables y se pueden aplicar de modo sencillo y seguro a grandes superficies de piel de modo aceptable por los pacientes en general, para el tratamiento o la prevención de psoriasis, dermatitis atópica (eczema atópico) y otros trastornos o enfermedades de la piel .
UY0001033404A 2010-05-26 2011-05-24 Composiciones farmacéuticas topicas UY33404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382146A EP2394653A1 (en) 2010-05-26 2010-05-26 Topical pharmaceutical compositions comprising mometasone furoate

Publications (1)

Publication Number Publication Date
UY33404A true UY33404A (es) 2011-12-01

Family

ID=42797321

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033404A UY33404A (es) 2010-05-26 2011-05-24 Composiciones farmacéuticas topicas

Country Status (33)

Country Link
US (2) US20140200203A1 (es)
EP (2) EP2394653A1 (es)
JP (1) JP5743241B2 (es)
KR (1) KR101790371B1 (es)
CN (1) CN102883725B (es)
AR (1) AR081765A1 (es)
AU (1) AU2011257586B2 (es)
BR (1) BR112012030006A2 (es)
CA (1) CA2794553C (es)
CL (1) CL2012003282A1 (es)
CO (1) CO6640244A2 (es)
DK (1) DK2575822T3 (es)
EA (1) EA022967B1 (es)
ES (1) ES2595250T3 (es)
HK (1) HK1177893A1 (es)
HR (1) HRP20161288T1 (es)
HU (1) HUE029818T2 (es)
IL (1) IL222163B (es)
LT (1) LT2575822T (es)
ME (1) ME02555B (es)
MX (1) MX2012013642A (es)
MY (1) MY160377A (es)
NZ (1) NZ602730A (es)
PL (1) PL2575822T3 (es)
PT (1) PT2575822T (es)
RS (1) RS55233B1 (es)
SG (2) SG184405A1 (es)
SI (1) SI2575822T1 (es)
SM (1) SMT201600342B (es)
TW (1) TWI473615B (es)
UY (1) UY33404A (es)
WO (1) WO2011147536A2 (es)
ZA (1) ZA201208420B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
KR20160030162A (ko) * 2013-07-11 2016-03-16 가부시키가이샤 폴라 파마 사용시 거품상을 나타내는 외용 조성물
GB2540764A (en) * 2015-07-24 2017-02-01 Fontus Health Ltd Topical composition
CN110770224B (zh) * 2017-03-10 2022-11-18 罗格斯新泽西州立大学 作为外排泵抑制剂的吲哚衍生物
EP3492068A1 (en) * 2017-12-01 2019-06-05 NCP NewCare Products GmbH Composition for treating onychomycosis
CN114767630A (zh) * 2022-06-06 2022-07-22 黑龙江中医药大学 一种治疗变应性鼻炎的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808610A (en) 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
NZ278198A (en) 1993-12-21 1997-12-19 Schering Corp Pharmaceutical compositions comprising mometasone furoate and salicyclic acid; use in treatment of psoriasis
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
CA2305256C (en) 1997-10-09 2005-05-17 Schering Corporation Mometasone furoate suspensions for nebulization
TR200201343A2 (tr) 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
US7312207B2 (en) 2003-05-23 2007-12-25 Taro Pharmaceuticals North America, Inc. Topical steroid cream formulations
DE102006034883A1 (de) 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
WO2008126076A2 (en) 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate

Also Published As

Publication number Publication date
JP5743241B2 (ja) 2015-07-01
TWI473615B (zh) 2015-02-21
IL222163B (en) 2018-01-31
EP2394653A1 (en) 2011-12-14
WO2011147536A3 (en) 2012-06-07
US9907807B2 (en) 2018-03-06
ME02555B (me) 2017-02-20
EP2575822B1 (en) 2016-07-06
EA201291335A1 (ru) 2013-04-30
CN102883725A (zh) 2013-01-16
CL2012003282A1 (es) 2013-01-25
ES2595250T3 (es) 2016-12-28
PT2575822T (pt) 2016-10-06
DK2575822T3 (en) 2016-10-17
CA2794553C (en) 2018-01-02
SMT201600342B (it) 2017-01-10
KR20130086137A (ko) 2013-07-31
AU2011257586B2 (en) 2014-04-17
PL2575822T3 (pl) 2017-01-31
CA2794553A1 (en) 2011-12-01
NZ602730A (en) 2014-03-28
CN102883725B (zh) 2015-04-01
AR081765A1 (es) 2012-10-17
CO6640244A2 (es) 2013-03-22
AU2011257586A1 (en) 2012-11-01
JP2013530149A (ja) 2013-07-25
HRP20161288T1 (hr) 2016-11-18
HUE029818T2 (en) 2017-04-28
EA022967B1 (ru) 2016-03-31
BR112012030006A2 (pt) 2016-08-02
KR101790371B1 (ko) 2017-10-25
LT2575822T (lt) 2016-10-10
MX2012013642A (es) 2013-05-06
MY160377A (en) 2017-03-15
ZA201208420B (en) 2013-09-25
US20160038512A1 (en) 2016-02-11
RS55233B1 (sr) 2017-02-28
EP2575822A2 (en) 2013-04-10
SI2575822T1 (sl) 2016-11-30
SG184405A1 (en) 2012-11-29
SG10201502252YA (en) 2015-05-28
US20140200203A1 (en) 2014-07-17
TW201204367A (en) 2012-02-01
HK1177893A1 (zh) 2013-08-30
WO2011147536A2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CO6640244A2 (es) Composiciones farmacéuticas tópicas
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
CR20130524A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
BR112013025878A2 (pt) composição farmacêutica e método para produzir uma composição farmacêutica
CO6710926A2 (es) Compuestos de n-heteroarilo
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112012017554B8 (pt) formulações de anestésicas locais formadoras de sólido para controle da dor
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112015012960A2 (pt) gel oral para o alívio da dor de dente
BR112014030288A2 (pt) composição farmacêutica
BR112013026564A2 (pt) uso de uma combinação
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
NI201200196A (es) Agentes terapéuticos 976
AR082366A1 (es) Formulacion dermocorticoide
MX2015008800A (es) Supresion de olor de los compuestos analgesicos organicos volatiles y metodo de uso.
AR118682A1 (es) Composición dermocosmética, de origen natural y orgánica, con efectos reparadores para pacientes oncológicos con radiodermitis; y procedimiento para su obtención
TH153704A (th) องค์ประกอบทางเภสัชกรรมสำหรับใช้เฉพาะที่

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200629